Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Conference Correspondent
Preliminary Evidence for Identifying Patterns of Organ Damage in Advanced Systemic Mastocytosis Subtypes
ASH 2021 Systemic Mastocytosis Wrap-Up
Conference Correspondent
— December 31, 2021
Criteria to assess presenting patterns of organ damage have not been extensively evaluated. Preliminary evidence suggests identifying these patterns could be useful in profiling organ dysfunction in avapritinib clinical trials.
Read Article
Cladribine as First-Line Therapy for Indolent and Advanced Systemic Mastocytosis
ASH 2021 Systemic Mastocytosis Wrap-Up
Conference Correspondent
— December 31, 2021
Cladribine has long been established as an efficient therapy in systemic mastocytosis and remains a valuable treatment option even as new therapies emerge.
Read Article
Whole Genome Sequencing Detects Chromosomal Aberrations Associated with Systemic Mastocytosis
ASH 2021 Systemic Mastocytosis Wrap-Up
Conference Correspondent
— December 31, 2021
Cytogenetic aberrations are rarely found by cytogenetics in systemic mastocytosis but are associated with advanced disease. Whole genome sequencing detects both chromosomal aberrations and non-
KIT
gene mutations and can be used as an alternative to cytogenetics for assessing disease risk.
Read Article
Assessing the Potential Role of Anti-CD117 CAR T-Cells for Targeted Therapy in Advanced Systemic Mastocytosis
ASH 2021 Systemic Mastocytosis Wrap-Up
Conference Correspondent
— December 31, 2021
CAR T-cell immunotherapy is highly efficient because of its ability to target specific tumor antigens. Preliminary evidence suggests that CAR T-cells directed against CD117, the KIT receptor, may emerge as a therapeutic option for advanced systemic mastocytosis.
Read Article
Genetic Testing for Hereditary Alpha-Tryptasemia in Patients Presenting with Mast-Cell Mediator Symptoms in the Absence of Symptoms of Mastocytosis
ASH 2021 Systemic Mastocytosis Wrap-Up
Conference Correspondent
— December 31, 2021
Hereditary alpha-tryptasemia may promote development of systemic mastocytosis. Screening for variations in copy number of the alpha tryptase gene may provide early evidence for diagnosis of mastocytosis.
Read Article
Medicare Patients with Advanced Systemic Mastocytosis Have a Higher Financial Burden and Use More Healthcare Resources
ASH 2021 Systemic Mastocytosis Wrap-Up
Conference Correspondent
— December 23, 2021
Advanced systemic mastocytosis often develops in patients aged >60 years but some younger patients qualify for Medicare due to preexisting disability. All patients with advanced systemic mastocytosis require more healthcare resources and have greater medical costs.
Read Article
Assessment of Prognostic Scoring Tools for Systemic Mastocytosis in a Real-World Setting
ASH 2021 Systemic Mastocytosis Wrap-Up
Conference Correspondent
— December 23, 2021
Clinical trials in systemic mastocytosis have led to the development of new prognostic scoring systems. Although effective in a controlled study, their usefulness in identifying high-risk patients in a real-world clinical setting requires further evaluation.
Read Article
New Study Investigates Safety and Efficacy of Bezuclastinib in Patients with Advanced Systemic Mastocytosis
ASH 2021 Systemic Mastocytosis Wrap-Up
Conference Correspondent
— December 23, 2021
Bezuclastinib treatment has shown clinical activity in advanced solid tumors with little toxicity. A phase 2 investigation seeks to determine its potential as a safe and effective option for KIT D816V–driven advanced systemic mastocytosis.
Read Article
PATHFINDER Study Reveals Potential for Avapritinib to Modify Progression of Advanced Systemic Mastocytosis
ASH 2021 Systemic Mastocytosis Wrap-Up
Conference Correspondent
— December 23, 2021
Avapritinib was recently approved for treatment in advanced systemic mastocytosis after demonstrating in clinicals trials the ability to improve hematologic and bone marrow responses in patients.
Read Article
Avapritinib Effectively Manages Advanced Systemic Mastocytosis in Patients with KIT D816V Mutations
ASH 2021 Systemic Mastocytosis Wrap-Up
Conference Correspondent
— December 23, 2021
KIT D816V mutations are highly associated with most cases of systemic mastocytosis. Avapritinib demonstrates efficacy in controlling disease progression in patients with
KIT D816V
mutations.
Read Article
Page 1 of 44
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma